Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31111003 | 0.83 | CYP4F2 (0.45) | CYP4F2CYP4A11ALDH1A1GAADRD2 | |
| SCHEMBL6152870 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11ALDH1A1GAAPTGS2 | |
| SCHEMBL31110728 | 0.81 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1GAADRD2 | |
| SCHEMBL31111112 | 0.80 | CYP4F2 (0.46) | CYP4F2CYP4A11ALDH1A1GAADRD2 | |
| SCHEMBL31111257 | 0.79 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1GAADRD2 | |
| SCHEMBL6977880 | 0.78 | CYP4F2 (0.59) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL31110697 | 0.77 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1GAADRD2 | |
| SCHEMBL31111166 | 0.77 | CYP4F2 (0.41) | CYP4F2CYP4A11ALDH1A1GAADRD2 | |
| SCHEMBL31111061 | 0.77 | CYP4F2 (0.41) | CYP4F2CYP4A11ALDH1A1GAADRD2 | |
| SCHEMBL8481900 | 0.76 | MTNR1A (0.57) | CYP4F2CYP4A11ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499604-A1 | DIHYDROBENZOFURAN AND DIHYDROBENZOTHIOPHENE 2,4-PENTAIDENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | Allergan, Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6720423-B2 | SKIN RELATED DISEASES; PROMOTE THE EXPRESSION OF OR BIND TO RECEPTORS BELONGING TO THE STEROID OR THYROID RECEPTOR SUPERFAMILY. | ALLERGAN, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003093257-A1 | DIHYDROBENZOFURAN AND DIHYDROBENZOTHIOPHENE 2,4-PENTAIDENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | RXRB, RXRA, RXRG | CYP4F2 53/4885CYP4A11 304/4885ALDH1A1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.